Education
About Us
Working with TipRanks
Follow Us
IntelGenx Technologies (IGXT)
:IGXT
RESEARCH TOOLSreports
Top Page
IntelGenx Technologies
(OTC:IGXT)
30Underperform
IntelGenx Technologies (IGXT) vs. S&P 500 (SPY)
Market Cap
$29.17M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)1.78
Revenue Growth20.11%
EPS Growth1.86%
CountryUS
Employees48
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding174,658,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)27.62
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
IntelGenx Technologies Business Overview & Revenue Model
Company DescriptionIntelGenx Technologies Corp. is a leading pharmaceutical company engaged in the development and manufacturing of innovative oral thin film products. The company focuses on the healthcare sector, specializing in novel drug delivery technologies that enhance the efficacy and safety of pharmaceutical products. IntelGenx's core services include the development of proprietary oral thin film formulations and the advancement of a robust product pipeline targeting a range of therapeutic areas.
How the Company Makes MoneyIntelGenx Technologies generates revenue primarily through the development and commercialization of its proprietary oral thin film drug delivery systems. The company earns money by entering into licensing and collaboration agreements with pharmaceutical companies, allowing them to utilize IntelGenx's technology for their own drug formulations. Additionally, IntelGenx generates income through contract development and manufacturing services, providing expertise and production capabilities for third-party products. Significant partnerships with established pharmaceutical companies also contribute to its earnings by expanding market reach and leveraging joint resources for product development and distribution.
IntelGenx Technologies Financial Statement Overview
Summary
IntelGenx Technologies is facing considerable financial difficulties across all major financial statement verticals. The company is struggling with profitability and cash flow generation, compounded by a problematic balance sheet with significant financial leverage and negative equity. These issues pose substantial risks to financial stability and future growth prospects.Income Statement
The company shows a persistent loss with negative net profit margins and declining revenue growth. Despite an improvement in gross profit compared to the previous year, the EBIT and EBITDA margins remain deeply negative, indicating ongoing operational challenges.25
Negative
Balance Sheet
The balance sheet reveals a highly leveraged position with a negative stockholders' equity, reflecting financial instability. The debt-to-equity ratio is unfavorable, and the negative equity ratio underscores the company's significant financial distress.15
Very Negative
Cash Flow
The cash flow statement highlights negative free cash flow growth, with operating cash flow consistently negative and insufficient to cover net income. The company faces challenges in generating positive cash flows from operations, which affects its overall liquidity.20
Very Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.05M | 1.04M | 950.00K | 1.53M | 1.54M | 742.00K | Gross Profit |
| -873.00K | -694.00K | -908.00K | -721.00K | 67.00K | 742.00K | EBIT |
| -10.50M | -9.49M | -9.41M | -7.98M | -6.26M | -9.55M | EBITDA |
| -8.16M | -7.68M | -8.64M | -7.04M | -5.11M | -8.73M | Net Income Common Stockholders |
| -11.03M | -9.93M | -11.97M | -9.31M | -8.25M | -11.87M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 10.99M | 2.28M | 2.53M | 9.95M | 2.24M | 1.91M | Total Assets |
| 20.02M | 8.28M | 9.19M | 17.91M | 11.12M | 11.02M | Total Debt |
| 7.95M | 15.50M | 10.51M | 11.47M | 9.92M | 8.79M | Net Debt |
| 1.14M | 13.22M | 9.30M | 7.52M | 8.71M | 7.45M | Total Liabilities |
| 10.03M | 20.53M | 12.61M | 14.03M | 12.07M | 10.73M | Stockholders Equity |
| 9.99M | -12.25M | -3.42M | 3.87M | -953.00K | 293.00K |
| Cash Flow | Free Cash Flow | ||||
| -7.14M | -6.71M | -9.79M | -7.28M | -5.89M | -8.72M | Operating Cash Flow |
| -7.03M | -6.53M | -9.52M | -7.17M | -5.77M | -8.20M | Investing Cash Flow |
| 1.23M | 1.17M | 3.51M | -5.07M | -526.00K | 3.21M | Financing Cash Flow |
| 3.99M | 6.78M | 2.96M | 15.49M | 6.24M | -690.00K |
IntelGenx Technologies Technical Analysis
Positive
0.17
Price Trends
0.17
Positive
0.17
Negative
0.17
Negative
Market Momentum
<0.01
Positive
49.60
Neutral
110.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IGXT, the sentiment is Positive. The current price of 0.17 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.17, and below the 200-day MA of 0.17, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.60 is Neutral, neither overbought nor oversold. The STOCH value of 110.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IGXT.
IntelGenx Technologies Risk Analysis
IntelGenx Technologies disclosed 31 risk factors in its most recent earnings report. IntelGenx Technologies reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
IntelGenx Technologies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $9.50B | 27.57 | 14.16% | ― | 24.81% | 33.67% | |
64 Neutral | $1.77B | 23.57 | 7.55% | ― | 8.94% | 5171.26% | |
48 Neutral | $6.36B | 1.28 | -45.04% | 2.64% | 19.24% | 1.69% | |
39 Underperform | $241.33M | ― | -16.20% | ― | 498.72% | 49.92% | |
30 Underperform | $29.17M | ― | 81.06% | ― | 20.11% | 1.86% |
* Healthcare Sector Average
Performance Comparison
IGXT
IntelGenx Technologies
0.17
>-0.01
-5.56%
NBIX
Neurocrine
90.72
-43.94
-32.63%
SUPN
Supernus Pharmaceuticals
31.67
1.43
4.73%
XOMA
Xoma
19.70
-6.15
-23.79%
IntelGenx Technologies Earnings Call Summary
Earnings Call Date: Nov 7, 2024 | % Change Since: 0.00% | Next Earnings Date: Mar 20, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in revenue growth and strategic partnerships, particularly in pharmaceuticals and animal health. However, challenges remain with product launches in Europe and FDA approvals. Overall, the company is optimistic about upcoming milestones and revenue streams.Highlights
Record Revenue Growth in Q4 2023
Total revenue for the fourth quarter increased by 146% to $426,000 compared to $173,000 for the same period last year.
First Purchase Order for RIZAFILM
Received first purchase order for RIZAFILM from Gensco Pharma, marking a significant milestone.
Settlement Agreement with Tilray
Entered into a settlement agreement with Tilray, including a purchase order for three new products.
Animal Health Advancements
Development and licensing agreements signed with Covenant Animal Health, potentially opening new commercial opportunities.
Montelukast Clinical Trials Progress
Completed dosing in Montelukast VersaFilm IIa trial; Phase II trial in Parkinson's disease to begin dosing soon.
Lowlights
No Progress with Exeltis in Spain
No appreciable progress by Exeltis for RIZAPORT in Spain; searching for a new commercial partner.
Ongoing Discussions with FDA
Continued discussions with FDA over buprenorphine buccal film program; no resolution yet.
Endo Bankruptcy Impact
Unclear future for specific products due to Endo's bankruptcy, with ongoing discussions but no definitive path forward.
Company Guidance
During the IntelGenx Q4 2023 earnings call, several key metrics and guidance were provided for the upcoming year. The company reported a significant increase in Q4 revenue to $426,000, marking a 146% growth compared to the previous year, primarily driven by increased R&D revenue. Total revenue for the year reached $1.039 million, with operating costs at $10.5 million, leading to a net comprehensive loss of $10.1 million, an improvement from the $11.5 million loss in 2022. The company anticipates a phase of rapid growth with the upcoming U.S. launch of RIZAFILM in Q2 2024 and plans to support this growth through a Reg A offering aimed at raising up to $20 million. They are also focused on finding a new commercial partner for RIZAPORT in Europe and advancing several clinical trials, including those for Montelukast VersaFilm in Alzheimer's and Parkinson's diseases. Additionally, IntelGenx is exploring expansion in its CDMO business model with expectations to initiate 3 to 5 new development projects in 2024.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.